ArticleAllergy2019
Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma.
Article in Allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- [Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps].HNO · 2021Pooled it
- Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.American journal of respiratory and critical care medicine · 2020Pooled it
- Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study.Dermatology and therapy · 2026Article
- Projecting the 20-year healthcare resource burden of asthma and COPD multimorbidity: insights from Singapore for integrated chronic respiratory care in South-East Asia.NPJ primary care respiratory medicine · 2026Article
- Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use.The World Allergy Organization journal · 2025Article
- The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps.Allergy and asthma proceedings · 2025Review
- Review
- Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).The World Allergy Organization journal · 2025Article
- The role of type 2 diabetes in the severity of adult asthma.Current opinion in allergy and clinical immunology · 2025Review
- Predicting Risk of Morbidities Associated with Oral Corticosteroid Prescription for Asthma.Pragmatic and observational research · 2025Article
- Systemic corticosteroid dose-response effects in asthma: an observational cohort study.ERJ open research · 2025Article
- Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.Advances in therapy · 2025Observational
- Biologic therapies for severe asthma with persistent type 2 inflammation.Australian prescriber · 2024Review
- Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma.Journal of asthma and allergy · 2024Article
- Maintenance OCS Were Used More Frequently Than Biologics in Patients with Uncontrolled GINA 4/5 Asthma in Germany in 2019.Journal of asthma and allergy · 2024Article
- Article
- Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.Biomedicines · 2023Article
- A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.Advances in therapy · 2023Review
- The use of systemic corticosteroids in asthma management in Latin American countries.The World Allergy Organization journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough systemic corticosteroid (SCS) treatment, irrespective of duration or dosage, is associated with adverse outcomes for patients with asthma, the longitudinal effects of this treatment on adverse outcomes, healthcare resource utilization (HCRU), and healthcare costs are unknown.
methodsWe identified patients initiating intermittent or long-term SCS who were diagnosed with active asthma from UK general practice with linked secondary care data. Control (non-SCS) patients were matched by sex and index date with those initiating SCS. Minimum baseline period was 1 year prior to index date; minimum follow-up duration was 2 years post-index date. Cumulative incidence of SCS-associated adverse outcomes and associated HCRU and costs were compared between SCS and non-SCS patient groups and among average SCS daily exposure categories. Associations between exposure and annualized HCRU and costs were assessed, adjusted for confounders.
resultsAnalyses included 9413 matched pairs. Median (interquartile range) follow up was as follows: SCS group: 7.1 (4.1-11.8) years; control group: 6.4 (3.8-10.0) years. Greater SCS dosages were correlated with greater cumulative incidence. For example, patients with type 2 diabetes receiving an average daily dosage of ≥7.5 mg had a 15-year cumulative incidence (37.5%) that was 1.5-5 times greater than those receiving lower dosages. HCRU and costs increased annually for SCS patients but not for non-SCS patients. Increases in all-cause adverse outcome (excluding asthma)-associated HCRU and costs were dose-dependent.
conclusionsOver the long term, adverse outcomes associated with SCS initiation were relatively frequent and costly, with a positive dosage-response relationship with SCS exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.